Ergoteles’s Supernus Pharmaceuticals SUPN Stock Holding History

Ergoteles’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,700	Closed	-$206K	–	1645
2021 Q2	$206K	Buy	+6,700	New	+$205K	﹤0.01%	1266

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ergoteles's SUPN Position: Q3 2021 in Review

Ergoteles sold out of Supernus Pharmaceuticals (SUPN) in Q3 2021, closing a stake of 6,700 shares — an estimated $206K sold.

Ergoteles first reported a position in SUPN in Q2 2021 and held it in 1 quarter. The position peaked at $206K in Q2 2021. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

Ergoteles reported no remaining Supernus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 6,700 Supernus Pharmaceuticals shares in Q3 2021, an estimated $206K.
Ergoteles first reported a position in Supernus Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Ergoteles's Supernus Pharmaceuticals position peaked at $206K in Q2 2021.
223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.